You are here

gevokizumab

Novartis returns to the discount aisle, buys Xoma’s failed PhIII drug for $31M

Endpoints

Fri, 08/25/17 - 09:53 am

cardiovascular disease

Decimated by clinical failure, Xoma turns to plan B

Fierce Biotech

Sat, 08/8/15 - 01:17 pm

clinical trials

endocrine disorders

Already with $1 billion in losses, Xoma plummets with late-stage drug failure

Bizjournals.com

Sat, 07/25/15 - 09:42 am

Behcet's uveitis

Xoma Is a Biotech Zombie in Need of a Kill Shot to the Head

TheStreet.com

Wed, 07/22/15 - 12:08 pm

3 Biotech Stocks With Upcoming Data That Could Be Huge

24/7 Wall St

Thu, 01/22/15 - 09:33 am

Ocular Therapeutix

This Week in Biotech: Put It in Print

Motley Fool

Sun, 03/9/14 - 01:31 pm

Rigel Pharmaceuticals

Sangamo BioSciences

NewLink Genetics

Xoma to stop testing drug as arthritis treatment

Yahoo/Reuters

Tue, 03/4/14 - 10:23 pm

XOMA completes enrollment in Phase 2 POC Gevokizumab trial

Yahoo/Fly on the Wall

Mon, 07/22/13 - 11:28 am

XOMA selects non-infectious anterior scleritis as next indication in POC program

The Fly on the Wall

Mon, 12/31/12 - 11:26 am

non-infectious anterior scleritis

XOMA Receives Orphan Drug Designation From U.S. Food & Drug Administration for Gevokizumab

Yahoo

Thu, 08/23/12 - 09:58 am

XOMA Enrolls for Gevokizumab Trials

Yahoo/Zacks

Sat, 07/7/12 - 11:22 am